With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.259808-67-8,1-Boc-3,3-Dimethylpiperazine,as a common compound, the synthetic route is as follows.
7-tert-butyl-5-(4,4-difluorocyclohexyl)furo[3,2-b]pyridine-2-carboxylic acid (910 mg, 2.697 mmol) and tert-butyl 3,3-dimethylpiperazine-1-carboxylate (578.0 mg, 2.697 mmol) was dissolved in DMF (3.3 mL). HATU (1.33 g, 3.51 mmol) and DIPEA (1.64 mL, 9.44 mmol) were successively added at RT. The reaction mixture was stirred overnight. EtOAc along with water were added. The phases were separated, and concentrated in vacuo to afford the title compound (950 mg, 66%). ESI-MS m/z calc. 533.3065, found 534.21. Rt: 2.48 min using Method C
As the paragraph descriping shows that 259808-67-8 is playing an increasingly important role.
Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; SAYEGH, Camil Elie; STURINO, Claudio; FOURNIER, Pierre-Andre; LACOSTE, Jean-Eric; DIETRICH, Evelyne; MARTEL, Julien; VALLEE, Frederic; (494 pag.)WO2016/154075; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics